Voltage-gated sodium channels (VGSCs) are the primary molecular targets of grayanotoxins. Understanding grayanotoxin pharmacology requires a foundational understanding of VGSC structure and gating. VGSCs are large integral membrane proteins — the α subunit, which contains the ion-conducting pore and the voltage-sensing machinery, is approximately 260 kDa and consists of four homologous domains (I–IV), each with six transmembrane segments (S1–S6). The S4 segments in each domain serve as voltage sensors, moving outward under membrane depolarisation to trigger the conformational changes that open the channel pore.
Channel gating involves three fundamental states: resting (closed, ready to activate), open (activated, conducting sodium ions), and inactivated (closed, not ready to re-activate until the membrane repolarises). The transition from open to inactivated occurs within milliseconds of opening and is mediated primarily by the fast inactivation gate — the intracellular III-IV linker loop that physically occludes the pore in a “hinged lid” mechanism. Recovery from inactivation requires membrane repolarisation and occurs over timescales of tens to hundreds of milliseconds, setting the refractory period for action potential generation.
Key Takeaways
- Grayanotoxins act at receptor site 2 within the transmembrane domains of voltage-gated sodium channels, preventing fast inactivation gate closure through lipophilic membrane partitioning and state-dependent binding.
- GTX binding shows use-dependence — effect increases with channel activation frequency — which may explain the prominence of effects in high-activity tissues (SA node, sensory neurons).
- Multiple Nav subtypes are affected, including cardiac Nav1.5, skeletal muscle Nav1.4, and peripheral neuronal Nav1.7 and Nav1.8, accounting for the multi-system toxidrome.
- CNS effects are generally mild in clinical presentations, likely due to limited blood-brain barrier penetration of the polar GTX molecules; dizziness is primarily haemodynamic in most cases.
- Grayanotoxins are pharmacological relatives of veratridine, batrachotoxin, and aconitine within the site 2 toxin class — a comparison that provides mechanism-based predictive power for understanding and managing the clinical picture.
Receptor Site 2: The Binding Locus
The VGSC toxin receptor site nomenclature (sites 1–6) was established to classify compounds by their binding location and pharmacological consequence. Site 1, extracellularly accessible, is the target of tetrodotoxin (TTX) and saxitoxin, which physically block ion conductance. Sites 2–6 are distinct locations that modulate gating rather than block conductance.
Site 2, the locus of grayanotoxin action, is located within the lipophilic environment of the channel’s transmembrane domains — accessible primarily through the membrane bilayer rather than through aqueous pathways. Mutagenesis studies have localised critical determinants of site 2 binding to residues in the S4-S5 linker regions of domains II and III, which are mechanistically involved in coupling voltage sensor movement to gate opening and inactivation. Binding of lipophilic site 2 toxins at these residues disrupts the coupling between voltage sensor movement and inactivation gate closure, stabilising the open-channel state.
The site 2 toxin pharmacological class includes, beyond the grayanotoxins, veratridine (from Veratrum alkaloids), batrachotoxin (from Phyllobates frogs), aconitine (from Aconitum species), and several synthetic compounds. These toxins share the outcome of impaired inactivation and consequent persistent sodium current, despite being structurally diverse. This convergent mechanism suggests that site 2 represents a pharmacologically vulnerable region of the VGSC architecture — a “soft underbelly” that multiple independent evolutionary lineages of toxic organisms have arrived at through different chemical means.
GTX Binding Kinetics
The kinetics of grayanotoxin binding to Nav channels have been studied using whole-cell and single-channel electrophysiology in native tissue and heterologous expression systems. GTX I and GTX III show use-dependent enhancement of their effect — that is, the magnitude of sodium current prolongation increases with repeated membrane depolarisations rather than being constant from the first application. This use-dependence implies that the toxin binds more readily or with higher affinity to the open or partially inactivated state of the channel than to the resting state.
This state-dependent binding has implications for understanding the clinical context. Tissues with high electrical activity — the rapidly firing SA node, active sensory neurons — are more susceptible to grayanotoxin-induced modification than quiescent tissues, because the high-state-transition frequency provides more binding opportunities. This may contribute to the relative prominence of SA node and sensory neuron effects in the clinical toxidrome, compared to effects in cardiac ventricular myocytes (which depolarise more slowly and less frequently than pacemaker cells).
The off-rate of grayanotoxin from site 2 is relatively slow compared to many reversible pharmacological agents, consistent with the sustained clinical effects observed over hours rather than minutes after cessation of exposure. The lipophilic character of GTX compounds may contribute to their persistence in the membrane environment and the slow off-rate from a hydrophobic binding pocket.
Nav Subtype Selectivity: Pharmacological Profile
The nine mammalian Nav subtypes (Nav1.1–Nav1.9) differ in amino acid sequence at and around the site 2 binding determinants, producing varying grayanotoxin affinities. The cardiac Nav1.5 isoform is particularly sensitive to grayanotoxins and site 2 toxins more generally, a pharmacological feature attributed to specific amino acid differences in the site 2 region compared to neuronal subtypes. Nav1.4 (skeletal muscle) and peripheral neuronal subtypes Nav1.7 and Nav1.9 also show meaningful GTX sensitivity.
The “resistance” of TTX-resistant Nav subtypes (Nav1.8 and Nav1.9) to tetrodotoxin — due to substitutions at the site 1 pore region — does not confer resistance to site 2 toxins, which act at a completely different location. Nav1.8, for example, is expressed in nociceptive C-fibres and may contribute to the prolonged sensory symptoms (particularly the dysaesthetic quality of paraesthesia) reported by some patients, as Nav1.8 supports repetitive firing and prolongs the depolarised state in nociceptor axons.
Central Nervous System Effects
The CNS effects of grayanotoxins — dizziness, altered consciousness, and in animal studies at high doses, seizure — reflect Nav channel actions at central neuronal subtypes. Nav1.1, Nav1.2, Nav1.3, and Nav1.6 are the predominant CNS isoforms, expressed across excitatory and inhibitory neurons in the brain and spinal cord. Persistent sodium current from grayanotoxin-modified channels disrupts the balance of excitation and inhibition and the precise timing required for coordinated neural signalling.
In human clinical cases, CNS effects are generally mild relative to cardiovascular effects — most likely because the blood-brain barrier limits CNS penetration of the relatively polar, multi-hydroxylated GTX molecules. The lipophilic membrane partitioning that facilitates access to site 2 from the membrane bilayer may not be sufficient to overcome barrier-mediated exclusion in the CNS. The dizziness reported clinically is therefore more likely to reflect haemodynamic compromise (cerebral hypoperfusion from bradycardia and hypotension) than direct GTX action on CNS neurons in most cases, though direct neuronal effects cannot be excluded at higher systemic concentrations.
Comparative Pharmacology: Grayanotoxins and Related Toxins
Comparing grayanotoxins pharmacologically with other site 2 toxins provides context for their relative potency and selectivity. Batrachotoxin — derived from Phyllobates dendrofrogs — is among the most potent known sodium channel toxins, active in the nanomolar range and producing irreversible effects due to covalent modification of the channel. Veratridine is active in the low micromolar range and produces similar but quantitatively weaker effects than batrachotoxin. Grayanotoxins (GTX I, III) are active in the low to mid-micromolar range in electrophysiological assays — less potent than batrachotoxin but clinically significant because the concentrations achievable through honey ingestion are within the pharmacologically relevant range.
Aconitine, from Aconitum species (monkshood), is the most directly clinically analogous toxin, producing a similar pattern of cardiovascular and neurological effects through site 2 sodium channel action. Aconitine poisoning from traditional herbal preparations is a recognised clinical entity in parts of Asia and shares many features of the mad honey toxidrome, including atropine responsiveness. Comparison of the two toxidromes has been used in teaching contexts to illustrate the predictive power of mechanism-based toxicology.
Research Frontiers
Current research interest in grayanotoxin pharmacology extends beyond toxicology into therapeutic pharmacology. The ability of low-dose grayanotoxin exposure to produce specific cardiovascular effects — controlled bradycardia, blood pressure reduction — has prompted investigation of the potential utility of grayanotoxin derivatives or analogues as pharmacological tools or even therapeutic agents. The narrow therapeutic index of existing GTX compounds and the complexity of their synthesis have limited practical progress, but the structural pharmacology work that has characterised their Nav binding provides a template for rational analogue design.
Additionally, the use of grayanotoxins as pharmacological probes to study Nav channel state-dependence and subtype selectivity continues in academic electrophysiology laboratories. The compound class offers a natural probe for site 2, complementing the extracellular site 1 probes (TTX, STX) that have been workhorses of ion channel pharmacology research for decades.
